Results From 10-Patient Case Study Lead to Phase III Clinical Trial for Patients with Duchenne Muscular Dystrophy
Cedars-Sinai Heart Institute researchers have found that a commonly prescribed drug restores blood flow to oxygen-starved muscles of boys with
Duchenne muscular dystrophy, a genetic muscle-wasting disease that rarely is seen in girls but affects one in 3,500 male babies, profoundly shortening life expectancy. It is the most common fatal disease that affects children.
Muscle weakness begins in early childhood, often causing deformity of the arms, legs and spine. Heart and respiratory muscles often begin to fail before children reach early teen years. Although steroid medications – which often are not well tolerated – and other therapies may ease symptoms and delay the most severe effects, no disease-specific treatment exists, and patients rarely survive into their 30s.
But in this case study of 10 boys with Duchenne muscular dystrophy, also called DMD, a single dose of a drug often prescribed for erectile dysfunction or pulmonary hypertension corrected defective blood vessel mechanisms and restored blood flow to exercising muscles.
“The effects were immediate and dramatic, raising the question: If a single dose restores blood flow to muscle while the drug is in the patient’s system, could ongoing tadalafil administration provide sustained benefits, possibly preserve muscle and slow disease progression? If so, this would offer a new therapeutic strategy for DMD, and we have launched a randomized Phase III clinical trial to find out,” said Ronald Victor, MD, director of the Cedars-Sinai Center for Hypertension, associate director of clinical research at the Heart Institute and the Burns and Allen Chair in Cardiology Research. He is the senior author of a highlighted article in the May 7 online edition of Neurology.
Duchenne muscular dystrophy results from a genetic defect that eliminates a protein called dystrophin in the membranes of muscle cells. For more than 25 years, Victor has studied DMD and a less aggressive but debilitating variant called Becker muscular dystrophy. This form of muscular dystrophy, usually diagnosed in early adulthood, is caused by a reduction, but not absence, of dystrophin.
Victor led a research team that in 2000 discovered that the blood flow abnormality in the muscles of children with DMD was caused by a loss of nitric oxide, a signaling chemical that normally tells blood vessels to relax during exercise, increasing blood flow and oxygenation.
In studies of mice bred to represent diseases of dystrophin deficiency, the researchers found that drugs prescribed for other disorders of blood vessel function could restore muscle blood flow and enable the animals to exercise more, with less muscle injury. Tadalafil, known by the brand names Cialis and Adcirca, and sildenafil, called Viagra and Revatio, have long been approved by the Food and Drug Administration to treat erectile dysfunction and pulmonary hypertension, a serious illness that restricts blood flow to the lungs.
Translating these findings to a human clinical trial, Victor and his colleagues published in 2012 a study showing that tadalafil fully restored blood flow in eight of nine patients with Becker muscular dystrophy.
In the new study, investigators found that when boys with Duchenne muscular dystrophy performed handgrip exercises, the major artery of the arm and the blood vessels in muscles of the forearm failed to respond the way they did in healthy boys of similar ages, 8 to 13. But when the boys with DMD were given a single dose of tadalafil, normal vessel function and blood flow were restored. Similar results occurred when sildenafil, a drug with a similar mechanism of action on vessels but a different chemical structure, was used in place of tadalafil.
“Steroids and cardiac-protective blood pressure medication are increasingly prescribed at early ages for patients with Duchenne muscular dystrophy in an effort to delay by a few years the most devastating effects of the disease. But these treatments have no effect on the blood vessel dysfunction that prevents muscles from getting the oxygen they need,” said Victor. “In contrast, in our study, a single dose of tadalafil or sildenafil had an immediate effect. These are well-studied, well-tolerated drugs that are already on the market. If additional study confirms their benefits, repurposing the drugs for muscular dystrophy patients could quickly transform clinical practice.”
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- Catabasis: Worth A Look Ahead Of Phase III Dataon March 24, 2020 at 3:20 pm
I reveal my plans to add to my position in the near-future. Catabasis Pharmaceuticals (CATB) has made excellent progress with their edasalonexent product candidate for Duchenne muscular dystrophy "DMD ...
- Duchenne Muscular Dystrophy (DMD) Treatment Market Analysis 2020 Global Industry Forecast to 2026on March 24, 2020 at 12:30 pm
Pune, India -- (SBWIRE) -- 03/24/2020 -- Duchenne Muscular Dystrophy (DMD) Treatment Market report provides detailed analysis and competitive analysis by region and other main information like a ...
- CureDuchenne Continues Focus as Champions for the Duchenne Community with Launch of Innovative Suite of Online Resourceson March 24, 2020 at 6:00 am
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--CureDuchenne, the leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, is rolling out a comprehensive suite of online ...
- Capricor Therapeutics to Host a Key Opinion Leader Call On Why Exosomes are Uniquely Suited for Vaccine Developmenton March 24, 2020 at 5:00 am
Exosomes Platform Technology Expanded to Potentially Combat the Novel Coronavirus ...
- Santhera Reports 2019 Annual Results and Highlights Pipeline Progress in Duchenne Muscular Dystrophyon March 23, 2020 at 11:00 pm
A conference call will be held today at 13:00 CET, 12:00 GMT, 08:00 EDT. Details are at the end of this statement. Net revenues ...
- Invitae and Muscular Dystrophy Association (MDA) Expand Access to No-Charge Genetic Testing in the U.S. and Canadaon March 23, 2020 at 5:31 pm
to offer sponsored, no-charge genetic testing to patients through the Detect Muscular Dystrophy program in MDA's care center network, a network of clinics at more than 150 of the nation's top ...
- Team Ethan: Meet the 10-year-old Decatur boy serving as MDA's National Ambassadoron March 21, 2020 at 10:00 pm
Like many young children, summer camp, from water tubing to zip lining to water sliding, represents Ethan LyBrand’s favorite time of year. It is where the 10-year-old Decatur boy, despite his battle ...
- Capricor Therapeutics' (CAPR) CEO Linda Marban on Q4 2019 Results - Earnings Call Transcripton March 18, 2020 at 5:21 pm
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2019 Earnings Conference Call March 18, 2020, 04:30 PM ET Company Participants AJ Bergmann - CFO Linda Marban - Pre ...
- Dr. Crystal Proud | Health Care Heroeson March 16, 2020 at 11:44 pm
“Now we have medicines that effectively deliver that missing gene to a child’s body." Proud has also participated in clinical trials for Duchenne muscular dystrophy, a disease that causes an inability ...
- Several Lower Extremity MR Biomarkers Predict Future Ambulatory Function in Patients With Duchenne Muscular Dystrophyon March 16, 2020 at 9:30 am
Researchers investigated the potential of lower extremity magnetic resonance biomarkers to serve as endpoints in clinical trials of therapeutics for Duchenne muscular dystrophy. Several magnetic ...
via Bing News